Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0776
    -0.0017 (-0.16%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2623
    +0.0001 (+0.01%)
     
  • USD/JPY

    151.3570
    -0.0150 (-0.01%)
     
  • Bitcoin USD

    69,863.98
    -549.37 (-0.78%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Why Puma Biotech (PBYI) is a Top Momentum Stock for the Long-Term

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Is This 1 Momentum Stock a Screaming Buy Right Now?

Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

Puma Biotech (PBYI)

Los Angeles, CA-based Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United States in late July 2017 for the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche’s Herceptin-based adjuvant therapy. The drug was also approved in the European Union in September 2018. Nerlynx recorded sales worth $189.1 million in 2021, down 3.9% year over year.

PBYI boasts a Momentum Style Score of A and VGM Score of A, and holds a Zacks Rank #2 (Buy) rating. Shares of Puma Biotech has seen some interesting price action recently; the stock is up 17.3% over the past one week and up 42.6% over the past four weeks. And in the last one-year period, PBYI has lost 14.5%. As for the stock's trading volume, 203,248.16 shares on average were traded over the last 20 days.

A company's earnings performance is important for momentum investors as well. For fiscal 2022, one analyst revised their earnings estimate higher in the last 60 days for PBYI, while the Zacks Consensus Estimate has increased $0.35 to $0.19 per share. PBYI also boasts an average earnings surprise of 317.6%.

Investors should take the time to consider PBYI for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement